arrow_back Back to App

Stem Cell Therapies: Renewed Funding and Research Advancement

This act extends funding for stem cell treatment programs, meaning greater access to therapies for patients. It also introduces regular scientific reviews to ensure new treatment methods can be quickly integrated into programs. Additionally, the act aims to increase the availability of cord blood units, which can help more people in need of transplants.
Key points
Increased funding for stem cell treatment programs until 2026, enhancing access to innovative therapies.
Regular scientific reviews every 2 years to ensure new therapies from adult stem cells and birthing tissues can be quickly made available to patients.
Strengthened efforts to increase the availability of cord blood units, crucial for transplants.
A report assessing the demand for specialists in regenerative medicine, potentially impacting career development in this field.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_288
Sponsor: Sen. Reed, Jack [D-RI]
Process start date: 2021-02-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

TRANSPLANT Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_288.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-08.

What are the main provisions?

Key points include:

  • Increased funding for stem cell treatment programs until 2026, enhancing access to innovative therapies.
  • Regular scientific reviews every 2 years to ensure new therapies from adult stem cells and birthing tissues can be quickly made available to patients.
  • Strengthened efforts to increase the availability of cord blood units, crucial for transplants.
  • A report assessing the demand for specialists in regenerative medicine, potentially impacting career development in this field.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Reed, Jack [D-RI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health